Novo Nordisk said it expects a decision by the fourth quarter of this year. The pharma giant already has one GLP-1 available in pill form under the name Rybelsus. The FDA cleared that drug in 2019 ...

A decision is expected in the fourth quarter of 2025.

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD ... negotiation for their key drug semaglutide, Wegovy/Ozempic/Rybelsus, in 2027 - it’s not clear how far the Trump ...

In a statement, a Novo Nordisk spokesperson said the disease is “very rare,” and is not considered an adverse drug reaction to semaglutide drugs such as Ozempic, Wegovy and Rybelsus.